Transcode announces first subject dosed in Phase 0 trial of TTX-MC138

TransCode Therapeutics announced the dosing of the first subject in its First-in-Human Phase 0 clinical trial. The Phase 0 trial is an open-label, single-center, microdose study intended to demonstrate delivery of the radio-labeled version of TransCode’s lead therapeutic candidate, TTX-MC138, to radiographically-confirmed metastases in subjects with advanced solid tumors. “We are pleased to have commenced our First-in-Human (FIH) clinical trial,” said TransCode’s Chief Executive Officer and co-founder, Michael Dudley. “The capability to deliver nucleic-acid based therapeutics to cancer represents a major turning point in the field of RNA because it opens up the possibility of developing an entire new class of drugs against most previously undruggable genetic targets. Overcoming this challenge could constitute an unprecedented step in unlocking therapeutic access to a range of cancers and beyond. Demonstrating successful delivery to cancer using TransCode’s proprietary TTX delivery platform could also enable progress towards more personalized cancer therapy guided by genetic profiling.